Latest News from Origin
AIM-market investment: Software Radio Technology
Although our team has extensive previous experience of AIM investing, SRT is the first quoted-market investment that Origin has made. SRT provides identification systems for use in marine applications and is the dominant global player in its markets. We are excited by both the size and growth of the market opportunity, and the quality of SRT’s products and management team.
Origin backs Monica Healthcare
We are excited to have invested in Monica Healthcare, which provides wireless telemetry solutions for monitoring maternal and foetal clinical indicators during labour.
Seed funding round for Up My Sport
Origin has provided seed capital to Up My Sport, a marketplace connecting sports instructors and coaches with participants. The company also provides associated administration and payment software solutions to sports professionals. The round included several prominent private investors, and the Angel Co-Fund.
Origin CEO interviewed
Tim de Vere Green, Origin’s CEO, has recently been interviewed by Anthony Miller of TechMarketView, regarding his recent experience of angel tech investing…
Co-invest with Origin Capital
For further details, please email Tim de Vere Green at firstname.lastname@example.org, or call us on 020 7733 5577.
UKBAA award for BWT
Our most recent investment, in semiconductor company Blu Wireless Technology, was voted Best Syndicated Deal at the 2014 UK Business Angels Investment Summit.
The deal was commended for its blend of angel, institutional and trade investors.
Lintbells: Brave and Bold
Lintbells, which produces health products for pets, won the “Market Mover” category of the Growth Accelerator’s “Brave and Bold” awards. Congratulations to the Lintbells team!
Apricus exit returns 2.5x
We invested in lifesciences business BioQuant, Apricus’ forerunner, in 2007, and again in 2008.
The company achieved a NASDAQ listing in 2009 and we sold our holding on the market over 2012 and 2013. We disposed of our shares in a spun-out subsidiary, Innovus Pharmaceuticals, on the US OTC market in Q1 this year, which completed our exit. Overall, the sales recouped 2.5x cash invested, representing a c.25% IRR over the holding period.
Origin CEO interviewed
Origin’s CEO, Tim de Vere Green, was recently interviewed by Anthony Miller of TechMarketView, regarding his experience of angel tech investing.
Vantage Power wins Shell Springboard
Vantage Power, our portfolio company developing retro-fit hybrid engines for buses, won the prestigious Shell Springboard competition earlier this week.